Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28891423

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2017 Nov 9
First author
Weber J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2017 Nov;14(11):647. doi: 10.1038/nrclinonc.2017.159.
    note
    Source null
    related pmid
    28948976
    relationship
    Comment in
  2. citation
    N Engl J Med. 2017 Nov 9;377(19):1888-1890. doi: 10.1056/NEJMe1711199.
    note
    Source null
    related pmid
    29117487
    relationship
    Comment in
  3. citation
    N Engl J Med. 2018 Feb 15;378(7):678-9. doi: 10.1056/NEJMc1716071.
    note
    Source null
    related pmid
    29446285
    relationship
    Comment in
  4. citation
    N Engl J Med. 2018 Feb 15;378(7):679. doi: 10.1056/NEJMc1716071.
    note
    Source null
    related pmid
    29446287
    relationship
    Comment in
  5. citation
    Br J Dermatol. 2018 Apr;178(4):817-820. doi: 10.1111/bjd.16347.
    note
    Source null
    related pmid
    29668089
    relationship
    Comment in
  6. citation
    N Engl J Med. 2019 Apr 4;380(14):1374-1376. doi: 10.1056/NEJMc1902228.
    note
    Source null
    related pmid
    30943345
    relationship
    Comment in

Authors and identifiers

  1. name
    Weber J
    type
    Author
  2. name
    Mandala M
    type
    Author
  3. name
    Del Vecchio M
    type
    Author
  4. name
    Gogas HJ
    type
    Author
  5. name
    Arance AM
    type
    Author
  6. name
    Cowey CL
    type
    Author
  7. name
    Dalle S
    type
    Author
  8. name
    Schenker M
    type
    Author
  9. name
    Chiarion-Sileni V
    type
    Author
  10. name
    Marquez-Rodas I
    type
    Author
  11. name
    Grob JJ
    type
    Author
  12. name
    Butler MO
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Weber J
    type
    Author
  2. name
    Mandala M
    type
    Author
  3. name
    Del Vecchio M
    type
    Author
  4. name
    Gogas HJ
    type
    Author
  5. name
    Arance AM
    type
    Author
  6. name
    Cowey CL
    type
    Author
  7. name
    Dalle S
    type
    Author
  8. name
    Schenker M
    type
    Author
  9. name
    Chiarion-Sileni V
    type
    Author
  10. name
    Marquez-Rodas I
    type
    Author
  11. name
    Grob JJ
    type
    Author
  12. name
    Butler MO
    type
    Author
bibliography ids
  1. nci-bib-860fbfac8e74207ef2f8d398
book metadata
content sha256
335cd67efc3a295a79d1ee6b81340d3b2c6cbe5728ae3885a344d27295fc4c69
document type
citation
dois
  1. 10.1056/NEJMoa1709030
electronic publication date
display
2017 Sep 10
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28891423
immutable id
pubmed:28891423@335cd67efc3a295a79d1ee6b81340d3b2c6cbe5728ae3885a344d27295fc4c69
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
19
name
The New England journal of medicine
nlm unique id
0255562
pages
1824-1835
volume
377
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2017 Nov;14(11):647. doi: 10.1038/nrclinonc.2017.159.
    note
    Source null
    related pmid
    28948976
    relationship
    Comment in
  2. citation
    N Engl J Med. 2017 Nov 9;377(19):1888-1890. doi: 10.1056/NEJMe1711199.
    note
    Source null
    related pmid
    29117487
    relationship
    Comment in
  3. citation
    N Engl J Med. 2018 Feb 15;378(7):678-9. doi: 10.1056/NEJMc1716071.
    note
    Source null
    related pmid
    29446285
    relationship
    Comment in
  4. citation
    N Engl J Med. 2018 Feb 15;378(7):679. doi: 10.1056/NEJMc1716071.
    note
    Source null
    related pmid
    29446287
    relationship
    Comment in
  5. citation
    Br J Dermatol. 2018 Apr;178(4):817-820. doi: 10.1111/bjd.16347.
    note
    Source null
    related pmid
    29668089
    relationship
    Comment in
  6. citation
    N Engl J Med. 2019 Apr 4;380(14):1374-1376. doi: 10.1056/NEJMc1902228.
    note
    Source null
    related pmid
    30943345
    relationship
    Comment in
outcomes validated
false
pmid
28891423
provenance
batch id
fb25b16edcb1373b70c1
provider
NCBI PubMed ESummary
record sha256
f006e0aeddeee440c132ec9fd847fd675463766d8732bc4389fca1b019499559
response sha256
182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
retrieved at
2026-09-09T23:47:28.490065+00:00
publication date
display
2017 Nov 9
precision
day
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28891423/
title
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Preserved source evidence · Not medical advice